STRENGTHS AND LIMITATIONS OF THIS STUDY
• Large randomized control trial that addresses duration of administration of Magnesium Sulfate, which fills an important gap in the literature and has significant implications for management of patients with eclampsia and preeclampsia with severe features. • The study is taking place in a low resource setting with a high incidence of preeclampsia and eclampsia and advanced disease at presentation • Data collection in a developing country setting with no electronic medical record may contribute to missing information and become a study limitation • Lack of blinding of patients and providers to group allocation is a study limitation, however, primary outcome (occurrence of seizure) and secondary outcomes (maternal: time to diuresis, clinical toxicities and complications; neonatal: birth outcomes) are objective measures
INTRODUCTION
Hypertensive disorders complicate 10% of pregnancies worldwide (1, 2) and preeclampsia occurs in 2-8% of all pregnancies globally (1) . In developing countries, hypertensive disorders account for 10-15% of maternal deaths (1, 2) . In Ghana, the incidence of hypertensive disorders in pregnancy has been estimated from a hospital based study as 7.6% (3) . Eclampsia contributes significantly to maternal mortality in developing countries. In Ghana, a case fatality of 3.9% has been reported, and institutional reports from two major tertiary level hospitals suggest hypertensive disorders have overtaken haemorrhage as the leading cause of maternal mortality (3, 4) .
While preeclampsia may not be preventable, the risk of eclampsia can be significantly reduced with good obstetric management (5, 6) . Magnesium Sulfate has been used for decades for the management of eclampsia and preeclampsia and is the anti-convulsant of choice for the management and prevention of eclamptic seizures (7, 8) . Good clinical efficacy has been reported with the use of Magnesium Sulfate in the management of preeclampsia despite wide disparities the dosing regimens and routes of administration (9, 6, 8, (10) (11) (12) .
There is lack of consensus in the existing literature about optimal duration and dosing of Magnesium Sulfate, as well as optimal therapeutic window. Therapeutic failures have been reported for doses considered both high and low (8) (9) (10) (11) (12) (13) . The narrow therapeutic window widely used in literature is challenged by pharmacokinetic studies that demonstrate that accepted international regimens sometimes fail to reach the minimum therapeutic threshold yet are associated with clinical efficacy (8, 14, 15) . The duration of treatment has also been questioned, and a wide range of different regimens are currently utilized in clinical practice. Some protocols such as the Sokoto (ultra-short) protocol demonstrated that just the standard loading dose of the Prichard regimen may be sufficient (11) .
In Korle Bu Teaching Hospital and other centres in Ghana, many patients do not complete the 24-hour maintenance course due to poor compliance due to discomfort associated with the repeated injections, side effects, and sometimes financial constraints; yet our observational experience has not demonstrated an increase in disease progression in this cohort of patients. Perhaps this is secondary to the efficacy demonstrated in shorter regimens like the 12-hour maintenance and ultra-short (6) . The cost to the individual and the healthcare system associated with the 24-hour maintenance course is significant. The determination of the minimum effective duration of treatment with proven clinical efficacy, minimum side effect profile and toxicity is likely to improve compliance, reduce waste and conserve resources in developing countries.
Problem Statement
Maternal morbidity and mortality resulting from preeclampsia and eclampsia remain high in many middle to low income countries. The case fatality of eclampsia is unacceptably high despite known interventions to reduce the progression to eclampsia. The current dosing regimens are at best empirical with several different regimens being utilized in clinical practice.
Previous studies comparing clinical efficacy of dosing regimens involved relatively small sample sizes and were not powered to detect clinical differences in toxicity and tolerability. Two small studies have compared outcomes using 12 hours versus 24 hours of Magnesium Sulfate using an intravenous infusion regimen (6, 12) . However, there are no studies that compare 12 hours versus 24 hours of Magnesium Sulfate using an intramuscular regimen, which is the most common method of administration in developing countries. Finally, the incidence of the various side effects or toxicities of magnesium sulfate with the Pritchard regimen has not been studied in the Ghanaian population, despite years of utilization of this regimen.
Justification
Magnesium sulfate remains the mainstay of treatment prevention of eclamptic seizures in patients with preeclampsia and the prevention of recurrent seizures in patients with eclampsia. The clinical efficacies reported with varying durations and routes of administration necessitates further research to determine the optimum effective duration with demonstrable clinical efficacy and low toxicity which will be cost efficient to the healthcare system, especially in low resource countries.
Our study therefore seeks to investigate and compare clinical response between the 12 hour versus 24 hour Modified Pritchard regimens. A significant reduction in cost is expected if the reduced duration of treatment proposed by this trial is adopted and there is a need to subject it to a rigorous clinical trial to assure maternal safety.
Aim and Objective
Aim: To compare the 12 hour versus 24 hour Modified Pritchard regimens of magnesium sulfate in the management of eclampsia and preeclampsia with severe features.
Objectives: 
METHODS AND ANALYSIS Study Design
An open label randomized control trial in which the Study arm will receive 12 hours of maintenance doses of Magnesium Sulfate and the Control arm will receive 24 hours of maintenance doses of Magnesium Sulfate. Participants will be enrolled into study groups by simple randomization using a computerized random number generation table.
Study Site
The Korle Bu Teaching Hospital (KBTH) is the country's premier teaching hospital and serves as a national referral hospital for the southern half of the country. It is a tertiary hospital with a bed capacity of 2000 and an average daily Outpatient Department attendance of 1500 patients. The maternity unit conducts about 9500 deliveries per year. Current standard of care at KBTH is a Modified Pritchard regimen of Magnesium Sulfate, with administration of a loading dose followed by 24 hours of maintenance dosing, starting at the time of diagnosis of eclampsia or preeclampsia with severe features.
Study Population
Accra is a cosmopolitan city with people of varied ethnic backgrounds and social status. It is expected that the sample will represent this diversity and be reflective of the nation. Participants will be patients receiving their prenatal care at Korle Bu Teaching Hospital, as well as referral cases from peri-urban and rural communities around Accra. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y The occurrence of eclamptic seizures in untreated cases of severe preeclampsia is 3.2%. In order to achieve a 25% reduction in the primary outcome (α= 0.05 and β=0.2) and according to a previous study (17) , 150 women will be sufficient, however to detect a 50% difference in the occurrence of side effect from 24% as reported by the Magpie trial(10) and to give the study a 90% power to detect the difference in side effects, 460 women (230 in each group) with severe preeclampsia will be sufficient. Lost to follow up is estimated as 5% in each category, therefore we will recruit 230 patients with eclampsia (115 in each group) and 480 patients with preeclampsia (240 in each group). See Figure 1 .
Inclusion

Study Duration
Conceptualization and securing of appropriate IRB approvals and funding and organization of trial materials lasted 18 months. Trial recruitment and follow up is estimated to last 1-2 years starting October 2018. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7 All women admitted the Korle Bu Teaching Hospital as a labouring or antepartum patient will be assessed by the on-call obstetric resident according to standard clinical practice. Based on initial history and physical examination, vitals signs, and laboratory values, clinical diagnoses will be made by the on-call obstetric team. If a patient has a clinical diagnosis of eclampsia or preeclampsia with severe features, she will be identified as a potential study participant. The on-call resident will review study inclusion and exclusion criteria. If a woman meets inclusion criteria, a research assistant will be notified to confirm inclusion/exclusion criteria and obtain informed consent. The participant will be randomized to the Treatment or Control group by simple randomization using a computerized random number generation table. A sticker will be placed on her chart to notify her clinical team of her participation and group assignment.
Protocol
The research assistant will commence data collection by extracting relevant demographic and clinical data, such as medical history, past obstetric history, and history of the index pregnancy from the participant's antenatal record and supplemented by direct interview of participants. During the hospitalization, we will prospectively document events such as timing of Magnesium Sulfate doses, timing of any seizures, mode and timing of delivery, maternal complications and Magnesium Sulfate toxicities. Neonatal information will be collected, including gestational age at delivery, birthweight, outcome of delivery (livebirth versus stillbirth), NICU admission, APGAR score at 1 and 5 minutes, and status at discharge (alive versus dead).
According to standard protocol at Korle Bu Teaching Hospital, all participants will have a detailed history and physical examination done at the time of admission. Complete blood counts, clotting profile, liver and renal function tests, and urine protein measurements will be performed. Strict fluid input and output monitoring will be done and recorded on the study fluids chart. All patients will have urethral catheterization retained for continuous bladder drainage until the last dose of the magnesium sulfate. All participants will be monitored for the entire duration of MgSO4 treatment by the on-call obstetrics team at least every 4 hours for blood pressure, patellar reflexes, respiratory rate, urine output, and occurrence of seizures. After completion of the MgSO4 injections, patients will have their blood pressure monitored every 4 hours until normalization of blood pressure, and subsequent discharge.
Apart from the duration of Magnesium Sulfate administration, all other clinical management of study participants will be carried out by the attending on-call obstetrician in accordance with the standard institutional care protocol at KBTH. This includes administration of antihypertenisves, decision on timing and mode of delivery, induction of labor, and initiation and interpretation of fetal monitoring. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Treatment Failure
The occurrence of a seizure after completion of the 3 rd maintenance doses and 6 th maintenance doses for the study and control groups respectively will be regarded as a treatment failure. These patients will have the 24 hour Modified Pritchard protocol re-started and completed if clinical assessment permits further Magnsium Sulfate therapy. After treatment failure, the management of further Magnesium Sulfate is at the clinical discretion of the attending on-call obstetrician.
The occurrence of clinical evidence of toxicity (absent tendon reflexes, respiratory depression, coma) after initiation of maintenance doses that necessitates discontinuation of further maintenance doses will also be regarded as a treatment failure. In the case of MgSO4 toxicities, the plan of management will be to stop further administration of MgSO4 and inject 1 g of calcium gluconate (10 mL of 10% solution) intravenously. The decision to re-initiate Magnesium Sulfate is at the clinical discretion of the attending on-call obstetrician.
Outcomes Measures
The primary outcome of this study will be the clinical efficacy of the Magnesium Sulfate regimen, defined as the absence of a seizure any time after the completion of the third maintenance dose (MD3) until discharge in the Treatment (12 hour) group and after the completion of the sixth maintenance dose (MD6) until discharge in the Control (24 hour) group.
Secondary outcome measures include:
Maternal: 1. The interval from initiation of treatment to the development of diuresis (diuresis will be defined as urine output > 400ml/4 hrs) 2. Clinical evidence of toxicity (absent tendon reflexes, RR <16cpm, coma) 3. Acute renal failure (urine output <25 mls/hr) after initiation of treatment 4. Pulmonary edema 5. Cerebrovascular accident (stroke) 6. Maternal death Neonatal:
1. Neonatal outcome at delivery (livebirth vs stillbirth) 2. APGAR scores at 1 and 5 minutes 
Statistical Design
Data will be entered into REDCap and analyses will be carried out using STATA. Primary study aim is to determine whether use of the 12 hour versus 24 hour Modified Pritchard regimens of magnesium sulfate impacts occurence of seizure. First, independent samples t-tests will be conducted to determine whether there are baseline differences between conditions (12 hour regimen, 24 hour regimen) in terms of demographics, obstetric history, medical history and index pregnancy (in the case of categorical variables, chi-square test of independence will be used). Next, the primary outcome of occurrence of a maternal seizure will be examined. Given the categorical nature of this outcome variable (yes seizure, no seizure), chi-square test of independence will be used to determine whether the probability of experiencing a seizure differed by condition. Finally, analyses will be conducted to assess secondary maternal and neonatal outcomes. In the case of continuous outcome variables independent samples t-tests will be conducted to assess whether condition predicts the continuous secondary outcome of interest. In the case of categorical outcome variables, chi-square tests of independence will be conducted to determine whether the incidence of the categorical secondary outcome of interest differed by condition. For all analyses, Fischer's exact test will be used instead of a chi-square test of independence should the incidence of an outcome occur in less than 5 individuals per condition and corrections will be applied to correct for multiple comparisons. Of note, outcome data will be collected for participants who discontinue or deviate from intervention protocols.
Data Handling
With approval from the IRB through the Korle Bu Teaching Hospital (KBTH), Dr Titus Beyuo (primary author) will oversee the management of data collection and data safety at Korle Bu Teaching Hospital in Accra, Ghana.
Patients' data collection forms will be initially identified by their "folder number" as given at their KBTH admission, as well as their name. This will allow subsequent data collection and integration throughout their hospital course, as well as data quality control as needed. Data collection forms will only be used and accessed by authorized study co-investigators and research assistants.
Data recorded on paper data collection forms will be reviewed by Dr. Titus Beyuo and then entered into a secure electronic data organization program (REDCap) using a password protected computer. Only authorized study co-investigators and research assistants will have access to this computer. The information entered into REDCap will only include unique study numbers and will not include participants names or any other personal identifying information.
The paper data collection forms will be stored securely in a locked cabinet in a locked office in the Obstetrics and Gynecology Department at KBTH, under the direction of Dr. Titus Beyuo. The records (data collection sheets) will be retained for the entire duration of the study, during which data will be accessible only by authorized investigators. After complete cleaning and quality assurance, identification . The Data and Patient Safety Board was created to assess the progress of the clinical study, and will review cumulative study data to evaluate safety, study conduct, and scientific validity and integrity of the study. Adverse events (anaphylaxis, allergic reaction to MgSO4, respiratory depression, coma) and severe adverse events (maternal morbidity or mortality secondary to anaphylaxis, allergic reaction to MgSO4, respiratory depression, coma) will be collected by the principal investigator, Dr. Beyuo, and reported to the Data and Patient Safety Review Board. Dr. Beyuo will also be responsible for communicating any adverse event or protocol modifications on behalf of the investigators to the Data and Patient Safety Board and the IRB.
Termination of study
The study may be terminated ahead of schedule upon recommendation of the Data and Patient Safety Board or by the IRB or by the investigators if interim analysis (planned for 6 months after initiation of study) shows greater than 1% difference in recurrent fits between the study and control arms.
Patient and Public Involvement Statement
This research was done without patient involvement. Patients were not invited to comment on the study design, interpret results, or contribute to the writing or editing of this document.
ETHICS AND DISSEMINATION
Ethics approval was obtained in Ghana through the Korle Bu Teaching Hospital IRB. University of Michigan involvement is limited to protocol development and statistical analysis of de-identified data, and has been granted a Not Regulated Determination by the University of Michigan IRB. The study has been registered with the Pan African Clinical Trial Registry through the South African Medical Research Council: PACTR201811515303983.
Results of the study will be shared at clinical forums at the Korle Bu Teaching Hospital and will be submitted for publication in an international peer-reviewed journal.
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ABSTRACT
Introduction: Hypertensive disorders of pregnancy continue to be a major contributor to maternal and perinatal morbidity and mortality. Magnesium Sulfate therapy is the standard of care for seizure prophylaxis and treatment for preeclampsia and eclampsia respectively, despite wide disparities in dosing regimens and routes of administration. This study compares the clinical efficacy of Magnesium Sulfate in the reduction of seizure occurrence or recurrence with the 12 hour versus 24 hour Modified Pritchard regimens in the management of severe preeclampsia and eclampsia.
Methods and Analysis:
This study is an open label randomized control trial. The study participants are patients admitted to the Korle Bu Teaching Hospital in Accra, Ghana with a diagnosis of antepartum, intrapartum, or postpartum eclampsia or preeclampsia with severe features. All study participants will be administered a loading dose of Magnesium Sulfate, followed by maintenance dosing. Participants in the Control group will receive magnesium sulfate for 24 hours after diagnosis, while those in the Treatment group will receive magnesium sulfate for 12 hours after diagnosis. The primary outcome of this study is the occurrence of a seizure any time after the completion of treatment in the assigned group. Secondary outcome measures include maternal health outcomes, Magnesium Sulfate toxicities, and fetal health outcomes. Data collection was started October 2018 with a target enrollment of 1245 participants with severe preeclampsia and 844 participants with eclampsia with a projected study period of 2-3 years.
Ethics and Dissemination:
Ethical approval was obtained from the Korle Bu Teaching Hospital IRB in Ghana. University of Michigan involvement is limited to protocol development and statistical analysis of de-identified data, and has been granted a Not Regulated Determination by the University of Michigan IRB. Results of the study will be shared at clinical forums at the Korle Bu Teaching Hospital and will be submitted for publication in an international peer-reviewed journal.
Trial Registration:
The study has been registered with the Pan African Clinical Trial Registry through the South African Medical Research Council: PACTR201811515303983. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
STRENGTHS AND LIMITATIONS OF THIS STUDY
INTRODUCTION
Hypertensive disorders complicate 10% of pregnancies worldwide [1] [2] and preeclampsia occurs in 2-8% of all pregnancies globally [1] . In developing countries, hypertensive disorders account for 10-15% of maternal deaths [1] [2] . In Ghana, the incidence of hypertensive disorders in pregnancy has been estimated from a hospital based study as 7.6% [3, 4] . Eclampsia contributes significantly to maternal mortality in developing countries. In Ghana, a case fatality of 3.9% has been reported, and institutional reports from two major tertiary level hospitals suggest hypertensive disorders have overtaken haemorrhage as the leading cause of maternal mortality [3] .
While preeclampsia may not be preventable, the risk of eclampsia can be significantly reduced with good obstetric management [5, 6] . Magnesium Sulfate has been used for decades for the management of eclampsia and preeclampsia and is the anti-convulsant of choice for the management and prevention of eclamptic seizures [7, 8] . Good clinical efficacy has been reported with the use of Magnesium Sulfate in the management of preeclampsia despite wide disparities the dosing regimens and routes of administration [5, 7, [9] [10] [11] [12] .
There is lack of consensus in the existing literature about optimal duration and dosing of Magnesium Sulfate, as well as optimal therapeutic window. Therapeutic failures have been reported for doses considered both high and low [7, [9] [10] [11] [12] . The narrow therapeutic window widely used in literature is challenged by pharmacokinetic studies that demonstrate that accepted international regimens sometimes fail to reach the minimum therapeutic threshold yet are associated with clinical efficacy [7, 13, 14] . The duration of treatment has also been questioned, and a wide range of different regimens are currently utilized in clinical practice. Some protocols such as the Sokoto (ultra-short) protocol demonstrated that just the standard loading dose of the Prichard regimen may be sufficient [11] .
In Korle Bu Teaching Hospital and other centres in Ghana, many patients do not complete the 24-hour maintenance course due to poor compliance due to discomfort associated with the repeated injections, side effects, and sometimes financial constraints; yet our observational experience has not demonstrated an increase in disease progression in this cohort of patients. Perhaps this is secondary to the efficacy demonstrated in shorter regimens like the 12-hour maintenance and ultra-short [5] . The cost to the individual and the healthcare system associated with the 24-hour maintenance course is significant. The determination of the minimum effective duration of treatment with proven clinical efficacy, minimum side effect profile and toxicity is likely to improve compliance, reduce waste and conserve resources in developing countries.
Problem Statement
Previous studies comparing clinical efficacy of dosing regimens involved relatively small sample sizes and were not powered to detect clinical differences in toxicity and tolerability. Two small studies have compared outcomes using 12 hours versus 24 hours of Magnesium Sulfate using an intravenous infusion regimen [5, 12] . However, there are no studies that compare 12 hours versus 24 hours of Magnesium Sulfate using an intramuscular regimen, which is a common method of administration in developing countries, particularly in Africa [15] . Finally, the incidence of the various side effects or toxicities of magnesium sulfate with the Pritchard regimen has not been studied in the Ghanaian population, despite years of utilization of this regimen.
Justification
Our study therefore seeks to investigate and compare clinical response between the 12 hour versus 24 hour Modified Pritchard regimens. A significant reduction in cost is expected if the reduced duration of treatment proposed by this trial is adopted and there is a need to subject it to a rigorous clinical trial to assure maternal safety. 
Aim and Objective
METHODS AND ANALYSIS Study Design
Study Site
Study Population
Accra is a cosmopolitan city with people of varied ethnic backgrounds and social status. It is expected that the sample will represent this diversity and be reflective of the nation. Participants will be patients receiving their prenatal care at Korle Bu Teaching Hospital, as well as referral cases from peri-urban and rural communities around Accra. 
Inclusion
Sample Size Estimation
An occurrence of a seizure is the primary outcome. In women with eclampsia, this will be a recurrent seizure and in women with preeclampsia with severe features, this will be their initial seizure.
Regarding Eclampsia, we assume that the recurrent seizure rate of women receiving 12 hours of Magnesium will be halfway between the seizure of rate of women receiving 24 hours of Magnesium (13.2%) and women receiving no Magnesium (27.9%) at 20.6% [17] . To detect a difference between 20.6% recurrent seizure in the 12 hour group and 13.2% recurrent seizure in the 24 hour group, a total sample size of 804 (402 in each group) is needed, assuming a two-sided test, 5% significance level and 80% statistical power.
Regarding preeclampsia, in the subgroup analysis of the Magpie Trial, women with severe preeclampsia have a 1.1% rate of seizure if treated with 24 hours of Magnesium [10] . In our current study, with a high risk population, we anticipate a 6% rate of seizures in women who receive no Magnesium based on study site department data. In an absence of data from the literature, we assume that the seizure rate of women receiving 12 hours of Magnesium will be halfway between the seizure of rate of women receiving 24 hours of Magnesium (1.1%) and women receiving no Magnesium (6%) at 3.55%. To detect a difference between 3.55% seizures in the 12 hour group and 1.1% seizures in the 24 hour group, a total sample size of 1,186 (593 in each group) is needed, assuming a two-sided test, 5% significance level and 80% statistical power.
Assuming 5% lost to followup and intervention discontinuation, 844 women with eclampsia (422 in each group) and 1245 women with severe preeclampsia (623 in each group) will be recruited. See Figure 1 for CONSORT flow-chart . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Protocol
All women admitted to the maternity ward of Korle Bu Teaching Hospital as an antepartum, labouring or postpartum patient will be assessed by the on-call obstetric resident according to standard clinical practice. Based on initial history and physical examination, vitals signs, and laboratory values, clinical diagnoses will be made by the on-call obstetric team. If a patient has a clinical diagnosis of eclampsia or preeclampsia with severe features, she will be identified as a potential study participant. The on-call resident will review study inclusion and exclusion criteria. If a woman meets inclusion criteria, a research assistant will be notified to confirm inclusion/exclusion criteria and obtain informed consent (see consent form suppplemenary file).
Participants will be enrolled into study groups by simple randomization using a computerized random number generation table (Random Number Generator version 3.0.56 for Mac). Using the table of random sequence of numbers (1 vs 2), sequentially numbered printed data collection forms will be labeled (1=control group; 2=treatment group) by researcher TB. After a participant is recruited and consented by the research assistant, the research assistant will be given the next numbered data collection form indicating the randomization group. The research assistants are not involved in the randomization process and do not have access or knowledge of the next treatment allocation. A sticker will be placed on the participants' chart to notify her clinical team of her participation and group assignment.
According to standard protocol at Korle Bu Teaching Hospital, all participants will have a detailed history and physical examination done at the time of admission. Complete blood counts, clotting profile, liver and renal function tests, and urine protein measurements will be performed. Strict fluid input and output monitoring will be done and recorded on the study fluids chart. All patients will have urethral catheterization retained for continuous bladder drainage until the last dose of the magnesium sulfate. All participants will be monitored for the entire duration of MgSO4 treatment by the on-call obstetrics team at least every 4 hours for blood pressure, patellar reflexes, respiratory rate, urine output, and occurrence of seizures. After completion of the MgSO4 injections, patients will have their blood pressure monitored every 4 hours until normalization of blood pressure, and subsequent discharge. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All doses of Magnesium Sulfate will be prepared and verified by the Korle Bu Teaching Hospital in accordance with standard hospital protocols. The loading doses will be constituted as 8mls of 50% solution diluted with 12mls of sterile saline to obtain 20mls of 4g MgSO 4, to be administered slowly over 15-20 minutes. Maintenance doses will be constituted as 10mls of 50% MgSO 4 solution to obtain 5g of MgSO 4, to be given as deep intramuscular (IM) injection. All doses of Magnesium Sulfate will be administered by clinical hospital nursing staff in accordance with standard hospital protocols.
Treatment Failure
Outcomes Measures
The primary outcome of this study will be the clinical efficacy of the Magnesium Sulfate regimen, defined as the absence of a seizure any time after the completion of the third maintenance dose (MD3) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Statistical Design
Data will be entered into REDCap and analyses will be carried out using STATA. Primary study aim is to determine whether use of the 12 hour versus 24 hour Modified Pritchard regimens of magnesium sulfate impacts occurence of seizure. First, bivariate analysis will be performed to determine whether there are baseline differences between conditions (12 hour regimen, 24 hour regimen) in terms of demographics, obstetric history, medical history and index pregnancy. Comparisons across regimens will be performed using independent samples t-tests for normally-distributed continuous variables, Wilcoxon Rank test for non-normally distributed continuous variables, and Chi-square, and Fisher's exact tests, where appropriate in the case of categorical variables. Next, the primary outcome of occurrence of a maternal seizure will be examined. Given the categorical nature of this outcome variable (yes seizure, no seizure), chi-square test of independence will be used to determine whether the probability of experiencing a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y seizure across conditions. Finally, analyses will be conducted to assess secondary maternal and neonatal outcomes. In the case of continuous outcome variables independent samples t-tests will be conducted to assess whether condition predicts the continuous secondary outcome of interest. In the case of categorical outcome variables, chi-square tests of independence will be conducted to determine whether the incidence of the categorical secondary outcome of interest differed by condition. For all analyses, Fischer's exact test will be used instead of a chi-square test of independence should the incidence of an outcome occur in less than 5 individuals per condition and [Bonferroni] corrections will be applied to correct for multiple comparisons. Number needed to treat and number needed to harm will be calculated for primary and secondary outcomes. All tests will be two-tailed. Of note, outcome data will be collected for participants who discontinue or deviate from intervention protocols.
Data Handling
The paper data collection forms will be stored securely in a locked cabinet in a locked office in the Obstetrics and Gynecology Department at KBTH, under the direction of Dr. Titus Beyuo. The records (data collection sheets) will be retained for the entire duration of the study, during which data will be accessible only by authorized investigators. After complete cleaning and quality assurance, identification numbers will be replaced by simple sequence numbers. This de-identified data will be exported from REDCap into STATA for statistical analysis. All authors will have access to the final study dataset.
Monitoring
Monitoring for quality and regulatory compliance will be overseen by the Korle Bu Teaching Hospital Scientific and Technical Committee in Ghana. An independent Data and Patient Safety Board was established at Korle Bu Teaching Hospital, consisting of Professor K. Nkyekyer (Consultant Obstetrician and chairman), Professor K.A. Bugyei (clinical pharmacologist and member), and Dr. Ayegua Hagan (statistician and member). The Data and Patient Safety Board was created to assess the progress of the clinical study, and will review cumulative study data to evaluate safety, study conduct, and scientific validity and integrity of the study. Adverse events (anaphylaxis, allergic reaction to MgSO4, respiratory depression, coma) and severe adverse events (maternal morbidity or mortality secondary to anaphylaxis, allergic reaction to MgSO4, respiratory depression, coma) will be collected by the principal investigator, 
Termination of study
Patient and Public Involvement Statement
This research was done without patient involvement. Patients were not invited to comment on the study design, interpret results, or contribute to the writing or editing of this document. Results of the study will be shared at clinical forums at the Korle Bu Teaching Hospital and will be submitted for publication in an international peer-reviewed journal. 
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Methods: Assignment of interventions (for controlled trials)
Allocation:
Sequence generation 16a
Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
______7_______
Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned ______7_______ Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 Methods for any additional analyses (eg, subgroup and adjusted analyses) ______9______
20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) _______9_____
Methods: Monitoring
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed ______10______ 21b
Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial _____9-10______
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